Trial name or title | Study SPAIN A Comparison of Symbicort Single Inhaler Therapy (Symbicort Turbuhaler 160/4.5 mcg, 1 Inhalation b.i. d. Plus as Needed) and Conventional Best Practice for the Treatment of Persistent Asthma in Adults - a 26-Week, Randomised, Open-Label, Parallel-Group, Multicentre Study. Estimated enrolment: 1000 |
Methods | Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study |
Participants | Inclusion Criteria:
Exclusion Criteria:
|
Interventions | A Comparison of Symbicort Single Inhaler Therapy (Symbicort Turbuhaler 160/4.5 meg, 1 Inhalation b.i.d. Plus as Needed) and Conventional Best Practice |
Outcomes | The primary outcome variable will be time to first severe asthma exacerbations. Exacerbations are considered an appropriate outcome variable by CPMP The definition of a severe asthma exacerbation is based on the same guideline A secondary objective is to collect safety data for treatment in the two treatment groups in adult patients with persistent asthma |
Starting date | Sept 2006 |
Contact information | |
Notes |